{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:47:17Z","timestamp":1787615237867,"version":"build-2736575974"},"reference-count":34,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Genet"],"accepted":{"date-parts":[[2016,11,1]]},"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>A high level of succinylacetone (SA) in blood is a sensitive, specific newborn screening marker for hepatorenal tyrosinemia type 1 (HT1, MIM 276700) caused by deficiency of fumarylacetoacetate hydrolase (FAH). Newborns with HT1 are usually clinically asymptomatic but show liver dysfunction with coagulation abnormalities (prolonged prothrombin time and\/or high international normalised ratio). Early treatment with nitisinone (NTBC) plus dietary restriction of tyrosine and phenylalanine prevents the complications of severe liver disease and neurological crises.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Six newborns referred for hypersuccinylacetonaemia but who had normal coagulation testing on initial evaluation had sequence variants in the <jats:italic>GSTZ1<\/jats:italic> gene, encoding maleylacetoacetate isomerase (MAAI), the enzyme preceding FAH in tyrosine degradation. Initial plasma SA levels ranged from 233 to 1282\u2005nmol\/L, greater than normal (&lt;24\u2005nmol\/L) but less than the initial values of patients with HT1 (16\u2005944\u201374\u2005377\u2005nmol\/L, n=15). Four individuals were homozygous for c.449C&gt;T (p.Ala150Val). One was compound heterozygous for c.259C&gt;T (p.Arg87Ter) and an intronic sequence variant. In one, a single heterozygous <jats:italic>GSTZ1<\/jats:italic> sequence variant was identified, c.295G&gt;A (p.Val99Met). Bacterial expression of p.Ala150Val and p.Val99Met revealed low MAAI activity. The six individuals with mild hypersuccinylacetonaemia (MHSA) were not treated with diet or nitisinone. Their clinical course has been normal for up to 13\u2005years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>MHSA can be caused by sequence variants in <jats:italic>GSTZ1<\/jats:italic>. Such individuals have thus far remained asymptomatic despite receiving no specific treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jmedgenet-2016-104289","type":"journal-article","created":{"date-parts":[[2016,11,22]],"date-time":"2016-11-22T22:10:32Z","timestamp":1479852632000},"page":"241-247","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":30,"title":["Hypersuccinylacetonaemia and normal liver function in maleylacetoacetate isomerase deficiency"],"prefix":"10.1136","volume":"54","author":[{"given":"Hao","family":"Yang","sequence":"first","affiliation":[{"name":"Division of Medical Genetics, Department of Pediatrics, CHU Sainte-Justine and Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"College of Animal Science and Technology, Northwest A&F University, Yangling, Shaanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8967-8640","authenticated-orcid":false,"given":"Walla","family":"Al-Hertani","sequence":"additional","affiliation":[{"name":"Departments of Medical Genetics and Paediatrics, Cumming School of Medicine, University of Calgary and Alberta Children's Hospital, Calgary, Alberta, Canada"},{"name":"Department of Medical Genetics, Centre universitaire de Sant\u00e9 McGill (CUSM), Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Cyr","sequence":"additional","affiliation":[{"name":"Service de G\u00e9n\u00e9tique m\u00e9dicale, D\u00e9partement de P\u00e9diatrie, Centre hospitalier universitaire de Sherbrooke (CHUS), Sherbrooke, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Laframboise","sequence":"additional","affiliation":[{"name":"Service de G\u00e9n\u00e9tique m\u00e9dicale, D\u00e9partement de P\u00e9diatrie, CHU de Qu\u00e9bec-Centre hospitalier de l'Universit\u00e9 Laval (CHUL), Qu\u00e9bec City, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Parizeault","sequence":"additional","affiliation":[{"name":"D\u00e9partement de P\u00e9diatrie, Centre Hospitalier de la Sagamie, Sagamie, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu Pei","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Medical Genetics, Department of Pediatrics, CHU Sainte-Justine and Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Rossignol","sequence":"additional","affiliation":[{"name":"Division of Medical Genetics, Department of Pediatrics, CHU Sainte-Justine and Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Th\u00e9r\u00e8se","family":"Berthier","sequence":"additional","affiliation":[{"name":"Programme qu\u00e9b\u00e9cois de D\u00e9pistage N\u00e9onatal Sanguin, CHU de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec City, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Gigu\u00e8re","sequence":"additional","affiliation":[{"name":"Programme qu\u00e9b\u00e9cois de D\u00e9pistage N\u00e9onatal Sanguin, CHU de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec City, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula J","family":"Waters","sequence":"additional","affiliation":[{"name":"Service de G\u00e9n\u00e9tique m\u00e9dicale, D\u00e9partement de P\u00e9diatrie, Centre hospitalier universitaire de Sherbrooke (CHUS), Sherbrooke, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant A","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Division of Medical Genetics, Department of Pediatrics, CHU Sainte-Justine and Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,11,22]]},"reference":[{"key":"2025100511141980000_54.4.241.1","unstructured":"Mitchell GA , Grompe M , Lambert M , Tanguay RM . Hypertyrosinemia. The Online Metabolic & Molecular Bases of Inherited Disease (OMMBID). 8th edn. New York: McGraw Hill, 2001:1777\u2013806."},{"key":"2025100511141980000_54.4.241.2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-8"},{"key":"2025100511141980000_54.4.241.3","doi-asserted-by":"publisher","DOI":"10.1007\/s100240010146"},{"key":"2025100511141980000_54.4.241.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2004.07.006"},{"key":"2025100511141980000_54.4.241.5","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-2633I"},{"key":"2025100511141980000_54.4.241.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2014.07.010"},{"key":"2025100511141980000_54.4.241.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199408113310603"},{"key":"2025100511141980000_54.4.241.8","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.22.13.4943-4951.2002"},{"key":"2025100511141980000_54.4.241.9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.74.10.4641"},{"key":"2025100511141980000_54.4.241.10","doi-asserted-by":"publisher","DOI":"10.1002\/bms.1200091003"},{"key":"2025100511141980000_54.4.241.11","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1997.6220"},{"key":"2025100511141980000_54.4.241.12","doi-asserted-by":"publisher","DOI":"10.1084\/jem.162.3.1060"},{"key":"2025100511141980000_54.4.241.13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0021-9258(18)65334-7","article-title":"Homogentisate metabolism: the isomerization of maleylacetoacetate by an enzyme which requires glutathione","volume":"220","author":"Edwards","year":"1956","journal-title":"J Biol Chem"},{"key":"2025100511141980000_54.4.241.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2012.05.022"},{"key":"2025100511141980000_54.4.241.15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110809"},{"key":"2025100511141980000_54.4.241.16","doi-asserted-by":"crossref","unstructured":"Wisse RP , Wittebol-Post D , Visser G , van der Lelij A . Corneal depositions in tyrosinaemia type I during treatment with Nitisinone. BMJ Case Rep 2012;2012. doi:10.1136\/bcr-2012-006301","DOI":"10.1136\/bcr-2012-006301"},{"key":"2025100511141980000_54.4.241.17","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-011-9394-5"},{"key":"2025100511141980000_54.4.241.18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4212\/cjhp.v68i3.1454","article-title":"Cost-consequence analysis of nitisinone for treatment of tyrosinemia type I","volume":"68","author":"Simoncelli","year":"2015","journal-title":"Can J Hosp Pharm"},{"key":"2025100511141980000_54.4.241.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63332-9"},{"key":"2025100511141980000_54.4.241.20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jchromb.2005.12.007","article-title":"A GC\/MS validated method for the nanomolar range determination of succinylacetone in amniotic fluid and plasma: an analytical tool for tyrosinemia type I","volume":"832","author":"Cyr","year":"2006","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2025100511141980000_54.4.241.21","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200111000-00005"},{"key":"2025100511141980000_54.4.241.22","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200002000-00007"},{"key":"2025100511141980000_54.4.241.23","doi-asserted-by":"publisher","DOI":"10.1042\/bj3310371"},{"key":"2025100511141980000_54.4.241.24","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.30"},{"key":"2025100511141980000_54.4.241.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199002153220704"},{"key":"2025100511141980000_54.4.241.26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/humu.10197","article-title":"How PAH gene mutations cause hyper-phenylalaninemia and why mechanism matters: insights from in vitro expression","volume":"21","author":"Waters","year":"2003","journal-title":"Hum Mutat"},{"key":"2025100511141980000_54.4.241.27","first-page":"65","article-title":"The control of flux","volume":"27","author":"Kacser","year":"1973","journal-title":"Symp Soc Exp Biol"},{"key":"2025100511141980000_54.4.241.28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1432-1033.1993.tb17802.x","article-title":"Responses of metabolic systems to large changes in enzyme activities and effectors. 2. The linear treatment of branched pathways and metabolite concentrations. Assessment of the general non-linear case","volume":"213","author":"Small","year":"1993","journal-title":"Eur J Biochem"},{"key":"2025100511141980000_54.4.241.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2008.04.018"},{"key":"2025100511141980000_54.4.241.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2008.02.014"},{"key":"2025100511141980000_54.4.241.31","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604554"},{"key":"2025100511141980000_54.4.241.32","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011405664"},{"key":"2025100511141980000_54.4.241.33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1515\/dmdi-2014-0015","article-title":"Chloral hydrate, through biotransformation to dichloroacetate, inhibits maleylacetoacetate isomerase and tyrosine catabolism in humans","volume":"30","author":"Shroads","year":"2015","journal-title":"Drug Metab Pers Ther"},{"key":"2025100511141980000_54.4.241.34","first-page":"328A","article-title":"Tyrosinemia type Ib caused by maleylacetoacetate isomerase deficiency: a new enzyme defect","volume":"23","author":"Berger","year":"1988","journal-title":"Pediatr Res"}],"container-title":["Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jmedgenet-2016-104289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T18:14:29Z","timestamp":1759688069000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmg.bmj.com\/lookup\/doi\/10.1136\/jmedgenet-2016-104289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,22]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,3,22]]},"published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1136\/jmedgenet-2016-104289"],"URL":"https:\/\/doi.org\/10.1136\/jmedgenet-2016-104289","relation":{},"ISSN":["0022-2593","1468-6244"],"issn-type":[{"value":"0022-2593","type":"print"},{"value":"1468-6244","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,22]]}}}